Viking Reports Positive Phase 1 Trial Results for VK2735 Dual Receptor Agonist

Viking Therapeutics has reported significant weight loss outcomes from a Phase 1 clinical trial of VK2735, a new dual GLP-1/GIP receptor agonist. The drug, taken orally in tablet form, was found to be safe and well-tolerated over a 28-day period, with a 5.3% weight reduction from baseline and a 3.3% mean weight loss compared to placebo. The study also showed that up to 57% of subjects treated with VK2735 achieved a weight loss of at least 5%, contrasting with 0% in the placebo group. The positive results have prompted Viking to plan a Phase 2 trial for the second half of 2024, focusing on obesity treatment.
In the trial, VK2735 exhibited a dose-dependent weight reduction, with the 40 mg dose group showing the most significant results. Notably, the drug's safety profile was favorable, with all treatment-related adverse events (TEAEs) being mild or moderate, and a majority of gastrointestinal issues were also mild. No serious adverse events were reported throughout the study.
The Phase 1 study was designed to assess the drug's safety and tolerability in healthy adults with a BMI of 30 kg/m² or higher. The primary objective was met with flying colors, indicating VK2735's potential as an oral treatment for obesity with a good safety profile.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for metabolic and endocrine disorders. Along with VK2735, they are also working on VK2809, a small molecule for lipid and metabolic disorders, and VK0214, a potential treatment for X-linked adrenoleukodystrophy (X-ALD).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!